Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

(AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based company said it had a loss of 21 cents.

Madison-based Exact Sciences Corp. on Tuesday reported third-quarter results worse than analysts expected. The biomedical giant best known for its Cologuard at-home colon cancer screening test ...

Let’s start with the cheapest, the yearly FIT, or fecal immunochemical test, which looks for fecal blood that might be caused ...

Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth ...

Wells Fargo analyst Brandon Couillard assigned a Buy rating to Exact Sciences (EXAS – Research Report) yesterday and set a price target ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...